2BB score and signals
Kymera Therapeutics, Inc.’s current 2BB score is 46 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 69 | High |
| Momentum | 59 | Stable |
| Financial strength | 21 | Weak |
| Quality | 97 | Very Strong |
| Risk | 36 | Low |
Company facts
| Headquarters | Watertown, Massachusetts, United States |
| Founded | 2015 |
| Employees | 273 |
| 52-week range | $55.26 – $130.05 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-24 | — | -1.2956 | — | $3.36M |
| 2026-10-29 | — | -1.2822 | — | $3.11M |
| 2026-08-05 | — | -0.7316 | — | $31.05M |
| 2026-04-30 | -0.71 | -0.8993 | $34.37M | $8.79M |
Related companies
